CIK 0001842295
- Non-accelerated filer
- Emerging growth company
Maze Therapeutics, Inc.
Sign in to watch- Ticker
- MAZE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 650-850-5070
- Business address
- 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- 4 Planned sale CSBO sold 7,500 shares at $25.37 ($190,299)
- 4 Planned sale President, R&D & CMO sold 15,000 shares at an average $29.46 ($441,904)
- 4 Planned sale SVP, Finance sold 2,500 shares at an average $29.44 ($73,611)
- 4 Planned sale CSBO sold 7,500 shares at an average $29.34 ($220,019)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale President, R&D & CMO sold 15,000 shares at an average $49.10 ($736,439)
- 4 Planned sale President, R&D & CMO sold 30,000 shares at an average $50.45 ($1,513,560)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale CSBO sold 7,500 shares at an average $45.43 ($340,723)
- 4 Derivatives Options or other derivatives
- 4 Planned sale SVP, Finance sold 5,000 shares at an average $45.20 ($226,011)
- 4 Derivatives Options or other derivatives
- 4 Planned sale President, R&D & CMO sold 15,000 shares at an average $46.02 ($690,334)
- 4 Planned sale SVP, Finance sold 5,000 shares at an average $46.04 ($230,219)
- 4 Planned sale CSBO sold 7,500 shares at an average $44.27 ($331,990)
- 4 Planned sale SVP, Finance sold 5,000 shares at $45.52 ($227,612)
- 4 Planned sale President, R&D & CMO sold 25,156 shares at $40.20 ($1,011,299)
- 4 Open-market sale Director sold 29,413 shares at an average $39.07 ($1,149,054)
Page 3 of 6 · 108 filings